Clinical trial

Identification of Integrin ab Expression in Lung Cancer Patients

NCT06167941

StatusCOMPLETED

Study typeOBSERVATIONAL

Start date2019-12-19

PhaseN/A

Study timeline

Study start (actual)2019-12-19Date precision: day

Registry last updated2023-12-13

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Expression of Integrin ανβ3 in Lung Cancerunresolved

Interventions

Lung cancer typesBIOLOGICAL

Sponsors & collaborators

Korea University Guro Hospitallead sponsor

Mapped research locations

SeoulSouth Korea1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT06167941 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.